TAK-242 was developed as a small-molecule selective inhibitor of TLR4 signaling that suppresses the increase in serum cytokine levels TNF-a, IL-1, and IL-6 in murine and porcine models of sepsis, as well as in LPS challenged healthy volunteers (9–11). The gene discussed is TLR4; the disease is Sepsis.